Bar coding helps improve patient safety.
- Published in:
- 2008
- Publication type:
- Journal Article
Works matching IS 1082801X AND DT 2008 AND VI 43 AND IP 1
Results: 20
1
2
Certolizumab pegol.
- Published in:
- 2008
- By:
- Publication type:
- Journal Article
3
Study results favor teriparatide over alendronate for treatment of glucocorticoid-induced osteoporosis.
- Published in:
- 2008
- Publication type:
- Journal Article
4
Equivalent dosing of irbesartan, valsartan, and losartan identified through formulary switch at a Veterans Affairs medical center.
- Published in:
- 2008
- By:
- Publication type:
- Journal Article
5
Biologic treatment of RA associated with increased risk of nonmelanotic skin cancer and melanoma.
- Published in:
- 2008
- Publication type:
- Journal Article
6
Safety labeling updates & new warnings.
- Published in:
- 2008
- Publication type:
- Journal Article
7
FDA actions in brief.
- Published in:
- 2008
- Publication type:
- Journal Article
8
New biologic.
- Published in:
- 2008
- Publication type:
- Journal Article
9
Drug Watch.
- Published in:
- Formulary, 2008, v. 43, n. 1, p. 32
- Publication type:
- Article
10
Bar coding helps improve patient safety.
- Published in:
- Formulary, 2008, v. 43, n. 1, p. 30
- By:
- Publication type:
- Article
11
Study results favor teriparatide over alendronate for treatment of glucocorticoid-induced osteoporosis.
- Published in:
- Formulary, 2008, v. 43, n. 1, p. 29
- Publication type:
- Article
12
Certolizumab pegol.
- Published in:
- Formulary, 2008, v. 43, n. 1, p. 22
- By:
- Publication type:
- Article
13
Equivalent dosing of irbesartan, valsartan, and losartan identified through formulary switch at a Veterans Affairs medical center.
- Published in:
- Formulary, 2008, v. 43, n. 1, p. 14
- By:
- Publication type:
- Article
14
Correction.
- Published in:
- 2008
- Publication type:
- Correction Notice
15
Safety.
- Published in:
- Formulary, 2008, v. 43, n. 1, p. 12
- Publication type:
- Article
16
Biologic treatment of RA associated with increased risk of nonmelanotic skin cancer and melanoma.
- Published in:
- Formulary, 2008, v. 43, n. 1, p. 12
- Publication type:
- Article
17
FDA actions in brief.
- Published in:
- Formulary, 2008, v. 43, n. 1, p. 11
- Publication type:
- Article
18
New biologic.
- Published in:
- Formulary, 2008, v. 43, n. 1, p. 10
- Publication type:
- Article
19
New molecular entity.
- Published in:
- Formulary, 2008, v. 43, n. 1, p. 10
- Publication type:
- Article
20
Pipeline preview.
- Published in:
- Formulary, 2008, v. 43, n. 1, p. 10
- Publication type:
- Article